ストックスクリーナーアプリを入手
1.725
2.54%
-0.045
前日終値:
$1.77
開ける：
$1.74
24時間の取引高:
209.03K
Relative Volume:
0.10
時価総額：
$259.31M
収益：
$42.17M
当期純損益:
$-183.12M
株価収益率:
-1.1846
EPS:
-1.4562
ネットキャッシュフロー:
$-138.51M
1週間 パフォーマンス:
+7.14%
1か月 パフォーマンス:
+2.07%
6か月 パフォーマンス:
+15.00%
1年 パフォーマンス:
+90.78%
1日の値動き範囲:
$1.705
$1.78
1週間の範囲:
$1.52
$1.85
52週間の値動き範囲:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
名前
Coherus Oncology Inc
セクター
電話
(650) 649-3530
住所
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.73 | 265.31M | 42.17M | -183.12M | -138.51M | -1.4562 |
VRTX
Vertex Pharmaceuticals Inc
|
455.43 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.88 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.96 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.13 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.76 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-23 | 開始されました | Oppenheimer | Outperform |
| 2025-09-04 | アップグレード | Maxim Group | Hold → Buy |
| 2024-08-16 | ダウングレード | UBS | Buy → Neutral |
| 2023-11-17 | 開始されました | Robert W. Baird | Outperform |
| 2023-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-07-24 | 開始されました | Citigroup | Buy |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2023-03-28 | アップグレード | UBS | Neutral → Buy |
| 2022-06-14 | 開始されました | UBS | Neutral |
| 2022-03-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 開始されました | BofA Securities | Neutral |
| 2020-04-17 | 開始されました | SunTrust | Buy |
| 2019-08-13 | 開始されました | Mizuho | Buy |
| 2019-08-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-02 | 繰り返されました | Maxim Group | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-07 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-09 | 繰り返されました | Maxim Group | Buy |
| 2017-08-08 | 繰り返されました | JP Morgan | Overweight |
| 2017-06-13 | 繰り返されました | Maxim Group | Buy |
| 2017-05-05 | 開始されました | BMO Capital Markets | Outperform |
| 2016-10-19 | 開始されました | Robert W. Baird | Outperform |
| 2016-09-07 | 開始されました | Maxim Group | Buy |
| 2016-07-27 | 開始されました | Citigroup | Buy |
| 2016-01-20 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Coherus Oncology Inc (CHRS) 最新ニュース
Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline - openPR.com
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Coherus Oncology announces proposed public offering of common stock - MSN
CHRS Technical Analysis & Stock Price Forecast - Intellectia AI
Coherus BioSciences Q4 2025 earnings preview - MSN
Coherus Oncology (CHRS) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen - MarketBeat
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - simplywall.st
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN
Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada
CHRS: Rapid oncology pipeline progress and strong LOQTORZI sales drive growth and pivotal trial plans - TradingView
Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com
Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Q4 2025 Earnings Call Transcript - MarketBeat
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: St - GuruFocus
Coherus Oncology (CHRS) Sees Strong Growth with LOQTORZI - GuruFocus
Coherus Oncology Reports Q4 Earnings Loss - National Today
Coherus Oncology Q4 Earnings Call Highlights - MarketBeat
CHRS: LOQTORZI sales doubled, debt slashed, and key oncology trials advance toward 2026 data - TradingView
CHRS: LOQTORZI revenue doubled, debt slashed, and pipeline advances set up major 2026 milestones - TradingView
CHRS Q4 Revenue Falls Short but Strategic Shift Shows Promise - GuruFocus
Coherus Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual ProfitNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Coherus Oncology: Fourth Quarter Financial Results Overview - Bitget
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Coherus Oncology (NASDAQ: CHRS) reports 2025 results and sharp debt cut - Stock Titan
Coherus Oncology: Q4 Earnings Snapshot - Barchart.com
Coherus Oncology Q4 revenue misses estimates - TradingView
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - The Manila Times
BRIEF-Coherus Oncology Q4 Sales USD 12.748 Million Vs. IBES Estimate USD 13.9 Million - TradingView
Cancer drug LOQTORZI sales double to $40.8M as trials near - Stock Titan
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect - GuruFocus
Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts - National Today
Coherus Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coherus BioSciences's Earnings Outlook - Benzinga
How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks - Yahoo Finance
Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com
CHRS: Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth - TradingView
CHRS: Rapid oncology transformation, strong LOQTORZI growth, and promising pipeline assets drive outlook - TradingView
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow - Quiver Quantitative
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewswire
Coherus Oncology Inc (CHRS) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):